{
  "docId": "019de073-9ed2-75f5-b4c4-69324b7a8310",
  "docSlug": "d4b095284b050177fedb9bcc804883cf",
  "documentTitle": "Albireo Pharma | Results Presentation Deck | 18 slides",
  "authorId": "albireo-pharma",
  "authorName": "Albireo Pharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 14,
  "pageCount": 18,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9ed2-75f5-b4c4-69324b7a8310/14",
  "deckHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310",
  "deckJsonHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310.json",
  "deckAnchorHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 1,
        "x": 0,
        "y": 0.83
      },
      "kind": "callout",
      "text": "Robust topline data to support regulatory filings – plans to complete in Q1 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55701690-5aa8-4a96-a07a-d0dd840877d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.86,
        "x": 0.07,
        "y": 0.208
      },
      "kind": "list",
      "text": "FIRST, ONLY & LARGEST PHASE 3 STUDY IN ALAGILLE SYNDROME: Randomized, placebo-controlled. DIVERSE, GLOBAL STUDY POPULATION: Trial enrolled patients from birth to young adults with both JAG1 and NOTCH2 mutations. ACHIEVED HIGHLY STATISTICAL SIGNIFICANCE: Pruritus, serum bile acids, sleep efficacy endpoints. WELL TOLERATED, NO DISCONTINUATIONS: Low drug-related diarrhea rate, almost all patients rolled over to extension study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b59a66e6-07b8-4ff6-af42-83d0672c8fbd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Bylvay ASSERT Phase 3 Results Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00fad6f3-b827-4801-8a31-7a8e66160523",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "706e309a-1edf-406d-a385-6a9dfcf6cec7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-14 present Bylvay as a solution, highlighting its efficacy and safety profile",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}